Abstract |
We compared the safety and efficacy of allogeneic stem cell transplantation (allo-SCT) after reduced-intensity conditioning using either unrelated umbilical cord blood (UCB) donors or matched-sibling donors (MSDs) for 21 adults at high risk with advanced Hodgkin lymphoma (UCB, n = 9; MSD, n = 12). Both groups were comparable except for younger age in the UCB cohort (median, 28 vs 42 years; P = .02). Neutrophil recovery occurred earlier in the MSD group (median, 7 vs 10 days; P = .02). All patients had sustained donor engraftment by day 60. Cumulative incidence of acute severe graft-versus-host-disease (33% vs 33%; P = .99), chronic graft-versus-host-disease (11% vs 33%; P = .24), and 100-day treatment-related mortality (11% vs 17%; P = .80) were comparable. With median follow-up periods of 17 and 24 months, the 2-year progression-free survival rates were 25% (95% confidence interval [95% CI], 0%-55%) for UCB and 20% (95% CI, 0%-44%) for MSD allo-SCT (P = .67). Our results suggest comparable outcomes for reduced-intensity allo-SCT using UCB or MSD in adults at high risk with advanced Hodgkin lymphoma.
|
Authors | Navneet S Majhail, Daniel J Weisdorf, John E Wagner, Todd E Defor, Claudio G Brunstein, Linda J Burns |
Journal | Blood
(Blood)
Vol. 107
Issue 9
Pg. 3804-7
(May 01 2006)
ISSN: 0006-4971 [Print] United States |
PMID | 16384924
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Cord Blood Stem Cell Transplantation
(adverse effects)
- Disease-Free Survival
- Female
- Graft vs Host Disease
(etiology)
- HLA Antigens
- Hematopoietic Stem Cell Transplantation
(adverse effects)
- Hodgkin Disease
(therapy)
- Humans
- Male
- Middle Aged
- Pilot Projects
- Prospective Studies
- Safety
- Siblings
- Tissue Donors
- Transplantation Chimera
(genetics)
- Transplantation Conditioning
(methods)
|